ClinicalTrials.gg
CompletedNCT04129164SSUpdated Apr 30, 2025Results posted

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

A Phase 2 interventional study of VIB4920 and Placebo in Sjögren's Syndrome, sponsored by Amgen. Completed at 63 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
22nd of 76
183 · median 57
Started
2019
with 5 others
Phase 2
30 of 111
3 open now
Registered
66th of 111
by date
Lead sponsor
7 of 111
Amgen

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 22nd largest by enrollment of the 76 interventional ones that give a count, is one of 6 that started in 2019, is one of 30 in phase 2, and was the 66th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

Read the detailed description

The study will enrol 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score \< 5. This study will include 3 periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized at 1:1 ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study drug discontinuation will not be eligible for treatment during Stage II. All participants will be followed for at least 12 weeks after their last dose of study drug administration.

Study acquired from Horizon in 2024.

03

Conditions studied

  • Sjögren's Syndrome

Browse trials for

Keywords

  • Sjögren's Syndrome
  • SS
  • VIB4920
  • MEDI4920
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria.
  • Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min (only for Population 2).
  • Have an ESSDAI score of >= 5 at screening; (not including the peripheral nervous system, central nervous system, and pulmonary domains) (only for Population 1).
  • Have an ESSPRI score of >= 5 at screening (only for Population 2).
  • Have an ESSDAI score of \< 5 at screening (only for Population 2).
  • Positive for either anti-Ro autoantibodies or rheumatoid factor, or both at screening.
  • Male and female participants who agree to follow protocol defined methods.
  • No active or untreated latent tuberculosis (TB).

Exclusion criteria

Exclusion Criteria:

  • Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the form (ICF).
  • Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
  • Concomitant polymyositis or dermatomyositis or systemic sclerosis.
  • Active or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma.
  • , , or infection.
  • More than one episode of herpes zoster and/or an opportunistic infection in the last 12 months.
  • Active viral, bacterial, or other infections or history of more than 2 infections requiring intravenous antibiotics within 12 months prior to signing the ICF.
  • Participants with corona virus disease 2019 (COVID-19) infection or who, in the judgment of the investigator, are at unacceptable risk of COVID-19 or its complications.
  • A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 2 weeks prior to randomization.
  • Received live (attenuated) vaccine within the 4 weeks prior to ICF signature.
  • Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell targeting therapy \< 3 months before randomization.
  • Injectable (including intraarticular) or treatment with > 10 mg/day dose oral prednisone or equivalent within 6 weeks prior to randomization (only for Population 1).
  • Treated with systemic corticosteroids for indications other than SS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2 weeks within 24 weeks prior to screening visit (only for Population 1).
  • Received previous treatment with anti-0L compounds at any time before screening.
  • Pregnant or lactating or planning to get pregnant during the duration of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    VIB4920 Dose 1 in Population 1

    Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.

    Drug: VIB4920 · Drug: Placebo

  • Placebo comparator
    Placebo in Population 1

    Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.

    Drug: VIB4920 · Drug: Placebo

  • Experimental
    VIB4920 Dose 1 in Population 2

    Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.

    Drug: VIB4920 · Drug: Placebo

  • Placebo comparator
    Placebo in Population 2

    Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.

    Drug: VIB4920 · Drug: Placebo

Interventions

  • Intravenous Dose 1.

    Also known as: Dazodalibep

  • DrugPlacebo

    Intravenous dose matched to VIB4920.

06

What researchers measure

Primary outcomes

  1. Population 1: Change From Baseline in ESSDAI at Day 169

    The ESSDAI is a systemic disease activity index for SS, assessing 12 domains (Constitutional, Salivary Glands, Lungs, Kidneys, Musculoskeletal, Peripheral Nervous System, Central Nervous System, Vascular, Gastrointestinal, Hematological, Ocular, and Extraglandular Manifestations). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change form baseline represents an increase in symptoms.

    Time frame: Baseline and Day 169

  2. Population 2: Change From Baseline in ESSPRI at Day 169

    The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms.

    Time frame: Baseline and Day 169

Secondary outcomes

  1. Population 1: Change From Baseline in ESSPRI at Day 169

    The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change from baseline represents an increase in symptoms.

    Time frame: Baseline and Day 169

  2. Population 1: Number of Participants Who Achieved ESSDAI[3] and ESSDAI[4] Response at Day 169

    The ESSDAI is a systemic disease activity index for primary Sjögren's syndrome, assessing 12 domains (e.g., cutaneous, renal, CNS, and biological). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change from baseline represents an increase in symptoms. ESSEDAI\[3\] and \[4\] responses were defined as a decrease of at least 3 or 4 points respectively in the ESSDAI score from the baseline value, measured at Day 169.

    Time frame: Day 169

  3. Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169

    The FACIT-Fatigue is a 13-item patient-reported questionnaire designed to assess the impact of fatigue on quality of life (QoL). Responses are scored from 0 (Not at all) to 4 (Very Much). The total score is the sum of all responses, ranging from 0 to 52, with higher scores indicating better QoL. A positive change from baseline represents an increase in QoL.

    Time frame: Baseline and Day 169

  4. Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169

    The OSDI is a validated tool for assessing vision-related function and dry eye disease severity (normal, mild, moderate, severe). It consists of 12 questions, with responses ranging from 0 (None of the time) to 4 (All of the time). Scores range from 0 to 100, as it is calculated by transforming the raw responses from the 12 questions into a standardized 0-100 scale, with higher scores indicating greater disability. A positive change from baseline indicates a worsening vision-related function.

    Time frame: Baseline and Day 169

  5. Patient Global Impression of Severity (PGIS) Score at Day 169

    The PGIS is a single-item measure that captures a patient's perception of overall symptom severity over the past week, using a 5-point categorical response scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with higher scores indicating greater symptom severity. Positive change from baseline values indicate worsening of symptoms severity.

    Time frame: Baseline and Day 169

  6. Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169

    The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms. Participants achieving an ESSPRI response were defined as at least a 1 point or 15% reduction from baseline in ESSPRI score at Day 169 without premature discontinuation from the study and without receiving rescue medications.

    Time frame: Day 169

  7. Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious TEAEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: Up to approximately 365 days

  8. Serum Concentration of VIB4920

    Blood samples were collected at the specified time points.

    Time frame: Day 1 pre-dose, Day 1 post-dose, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141 pre-dose, Day 141 post-dose, Day 169 pre-dose, Day 169 post-dose, Day 197, Day 225, Day 253, Day 281, Day 309, Day 365

07

Results

Posted Apr 30, 2025

Participant flow

Participants were recruited across 70 international sites between November 2019 and March 2023.

Participant flow — Overall Study
MilestonePopulation 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/Placebo
Started38365554
Completed stage i37345249
Completed35324747
Not completed3487
Withdrew: Non-compliance with procedures0020
Withdrew: Adverse event0020
Withdrew: Pregnancy0001
Withdrew: Withdrawal by subject3246
Withdrew: Death0100
Withdrew: Lost to follow-up0100

Outcome measures

PrimaryPopulation 1: Change From Baseline in ESSDAI at Day 169

The ESSDAI is a systemic disease activity index for SS, assessing 12 domains (Constitutional, Salivary Glands, Lungs, Kidneys, Musculoskeletal, Peripheral Nervous System, Central Nervous System, Vascular, Gastrointestinal, Hematological, Ocular, and Extraglandular Manifestations). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change form baseline represents an increase in symptoms.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Score on scale
Population 1: Change From Baseline in ESSDAI at Day 169
Score on scalePopulation 1: PlaceboPopulation 1: VIB4920
Population 1: Change From Baseline in ESSDAI at Day 169-4.1 ± 0.6-6.3 ± 0.6
PrimaryPopulation 2: Change From Baseline in ESSPRI at Day 169

The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Score on scale
Population 2: Change From Baseline in ESSPRI at Day 169
Score on scalePopulation 2: PlaceboPopulation 2: VIB4920
Population 2: Change From Baseline in ESSPRI at Day 169-0.53 ± 0.23-1.80 ± 0.23
SecondaryPopulation 1: Change From Baseline in ESSPRI at Day 169

The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change from baseline represents an increase in symptoms.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Score on scale
Population 1: Change From Baseline in ESSPRI at Day 169
Score on scalePopulation 1: PlaceboPopulation 1: VIB4920
Population 1: Change From Baseline in ESSPRI at Day 169-1.12 ± 0.29-1.80 ± 0.31
SecondaryPopulation 1: Number of Participants Who Achieved ESSDAI[3] and ESSDAI[4] Response at Day 169

The ESSDAI is a systemic disease activity index for primary Sjögren's syndrome, assessing 12 domains (e.g., cutaneous, renal, CNS, and biological). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (\<5), moderate (5-13), and high (≥14). A positive change from baseline represents an increase in symptoms. ESSEDAI\[3\] and \[4\] responses were defined as a decrease of at least 3 or 4 points respectively in the ESSDAI score from the baseline value, measured at Day 169.

Time frame:
Day 169
Reported as:
Count of participants · Participants
Population 1: Number of Participants Who Achieved ESSDAI[3] and ESSDAI[4] Response at Day 169
ParticipantsPopulation 1: PlaceboPopulation 1: VIB4920
ESSDAI[3] Day 1692226
ESSDAI[4] Day 1691824
SecondaryChange From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169

The FACIT-Fatigue is a 13-item patient-reported questionnaire designed to assess the impact of fatigue on quality of life (QoL). Responses are scored from 0 (Not at all) to 4 (Very Much). The total score is the sum of all responses, ranging from 0 to 52, with higher scores indicating better QoL. A positive change from baseline represents an increase in QoL.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Score on scale
Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169
Score on scalePopulation 1: PlaceboPopulation 1: VIB4920Population 2: PlaceboPopulation 2: VIB4920
Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 1695.8 ± 1.68.1 ± 1.62.8 ± 1.48.1 ± 1.4
SecondaryChange From Baseline in Ocular Surface Disease Index (OSDI) at Day 169

The OSDI is a validated tool for assessing vision-related function and dry eye disease severity (normal, mild, moderate, severe). It consists of 12 questions, with responses ranging from 0 (None of the time) to 4 (All of the time). Scores range from 0 to 100, as it is calculated by transforming the raw responses from the 12 questions into a standardized 0-100 scale, with higher scores indicating greater disability. A positive change from baseline indicates a worsening vision-related function.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Score on scale
Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169
Score on scalePopulation 1: PlaceboPopulation 1: VIB4920Population 2: PlaceboPopulation 2: VIB4920
Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169-14.02 ± 3.06-16.00 ± 3.22-8.52 ± 2.94-13.95 ± 2.95
SecondaryPatient Global Impression of Severity (PGIS) Score at Day 169

The PGIS is a single-item measure that captures a patient's perception of overall symptom severity over the past week, using a 5-point categorical response scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with higher scores indicating greater symptom severity. Positive change from baseline values indicate worsening of symptoms severity.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Score on scale
Patient Global Impression of Severity (PGIS) Score at Day 169
Score on scalePopulation 1: PlaceboPopulation 1: VIB4920Population 2: PlaceboPopulation 2: VIB4920
Patient Global Impression of Severity (PGIS) Score at Day 169-0.5 ± 0.1-0.6 ± 0.1-0.4 ± 0.1-0.6 ± 0.1
SecondaryPopulation 2: Number of Participants Who Achieved ESSPRI Response at Day 169

The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms. Participants achieving an ESSPRI response were defined as at least a 1 point or 15% reduction from baseline in ESSPRI score at Day 169 without premature discontinuation from the study and without receiving rescue medications.

Time frame:
Day 169
Reported as:
Count of participants · Participants
Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169
ParticipantsPopulation 2: PlaceboPopulation 2: VIB4920
Population 2: Number of Participants Who Achieved ESSPRI Response at Day 1691836
SecondaryNumber of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious TEAEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events (CTCAE).

Time frame:
Up to approximately 365 days
Reported as:
Count of participants · Participants
Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)
ParticipantsPopulation 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/Placebo
Stage 1 TEAEs23283837
Stage 1 SAEs0113
Stage 1 Grade ≥ 30212
Stage 1 Fatal AEs0100
Stage 2 TEAEs28253432
Stage 2 SAEs1312
Stage 2 Grade ≥ 30203
Stage 2 Fatal AEs0000
SecondarySerum Concentration of VIB4920

Blood samples were collected at the specified time points.

Time frame:
Day 1 pre-dose, Day 1 post-dose, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141 pre-dose, Day 141 post-dose, Day 169 pre-dose, Day 169 post-dose, Day 197, Day 225, Day 253, Day 281, Day 309, Day 365
Reported as:
Mean · mg/L
Serum Concentration of VIB4920
mg/LPopulation 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/Placebo
Day 1 pre-dose—0.002 ± 0.013—0.002 ± 0.013
Day 1 post-dose—470.370 ± 111.047—496.984 ± 182.915
Day 15—97.058 ± 26.480—111.636 ± 56.244
Day 29—128.228 ± 31.805—141.365 ± 100.163
Day 57—62.363 ± 25.562—80.093 ± 64.358
Day 85—53.716 ± 21.300—68.812 ± 60.349
Day 113—52.796 ± 29.229—66.778 ± 59.558
Day 141 pre-dose—49.318 ± 27.952—80.912 ± 125.684
Day 141 post-dose0.577 ± NA525.702 ± 155.28625.004 ± NA532.216 ± 241.670
Day 169 pre-dose—50.390 ± 18.717—54.031 ± 30.161
Day 169 post-dose469.366 ± 92.41365.459 ± 113.805572.071 ± 200.23557.018 ± 31.592
Day 19739.535 ± 16.65510.808 ± 9.98239.399 ± 15.32514.958 ± 28.728
Day 22546.885 ± 21.6331.903 ± 1.59473.173 ± 194.8361.979 ± 1.624
Day 25345.069 ± 23.1430.360 ± 0.34363.950 ± 77.0060.427 ± 0.485
Day 28146.368 ± 23.3490.086 ± 0.16054.050 ± 50.5950.139 ± 0.340
Day 30952.409 ± 23.7540.008 ± 0.02644.732 ± 24.8880.018 ± 0.044
Day 3652.446 ± 2.5360 ± 01.531 ± 1.0170.003 ± 0.014

Adverse events

Collected over Up to approximately 365 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Population 1: Placebo (Stage I)0/38 (0%)0/38 (0%)18/38 (47.4%)
Population 1: VIB4920 (Stage I)1/36 (2.8%)1/36 (2.8%)20/36 (55.6%)
Population 1: VIB4920 (Stage II)0/37 (0%)1/37 (2.7%)24/37 (64.9%)
Population 1: Placebo (Stage II)0/34 (0%)3/34 (8.8%)22/34 (64.7%)
Population 2: Placebo (Stage I)0/55 (0%)1/55 (1.8%)21/55 (38.2%)
Population 2: VIB4920 (Stage I)0/54 (0%)3/54 (5.6%)21/54 (38.9%)
Population 2: VIB4920 (Stage II)0/52 (0%)1/52 (1.9%)20/52 (38.5%)
Population 2: Placebo (Stage II)0/49 (0%)2/49 (4.1%)21/49 (42.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPopulation 1: Placebo (Stage I)Population 1: VIB4920 (Stage I)Population 1: VIB4920 (Stage II)Population 1: Placebo (Stage II)Population 2: Placebo (Stage I)Population 2: VIB4920 (Stage I)Population 2: VIB4920 (Stage II)Population 2: Placebo (Stage II)
Drug-induced liver injuryHepatobiliary disorders0/380/360/371/340/550/540/520/49
Multiple injuriesInjury, poisoning and procedural complications0/380/360/371/340/550/540/520/49
Cervical dysplasiaReproductive system and breast disorders0/380/360/371/340/550/540/520/49
Deep vein thrombosisVascular disorders0/380/360/371/340/550/540/520/49
DeathGeneral disorders0/381/360/370/340/550/540/520/49
COVID-19Infections and infestations0/381/360/370/340/550/540/520/49
Cholecystitis chronicHepatobiliary disorders0/380/361/370/340/550/540/520/49
Urinary tract infectionInfections and infestations0/380/360/370/340/550/540/521/49
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/380/360/370/340/550/540/521/49
Atrial flutterCardiac disorders0/380/360/370/340/550/541/520/49
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPopulation 1: Placebo (Stage I)Population 1: VIB4920 (Stage I)Population 1: VIB4920 (Stage II)Population 1: Placebo (Stage II)Population 2: Placebo (Stage I)Population 2: VIB4920 (Stage I)Population 2: VIB4920 (Stage II)Population 2: Placebo (Stage II)
COVID-19Infections and infestations0/384/366/376/347/558/549/525/49
Upper respiratory tract infectionInfections and infestations2/383/365/375/344/552/542/522/49
HeadacheNervous system disorders5/384/364/372/342/552/544/521/49
NasopharyngitisInfections and infestations0/381/363/370/345/555/542/526/49
DiarrhoeaGastrointestinal disorders0/383/362/373/340/553/541/520/49
Ligament sprainInjury, poisoning and procedural complications0/383/360/370/340/550/541/520/49
DizzinessNervous system disorders1/383/361/370/340/550/540/520/49
Oral herpesInfections and infestations2/380/363/370/340/550/540/521/49
ArthralgiaMusculoskeletal and connective tissue disorders1/380/363/372/341/550/541/523/49
SyncopeNervous system disorders1/380/363/370/340/550/540/520/49

Baseline characteristics

Full Analysis Set (FAS): included all randomized participants who received any dose of investigational product, analyzed according to the randomized treatment.

Age, Customized
Age, Customized(participants)Population 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/PlaceboTotal
18-85 years38365554183
Sex: Female, Male
Sex: Female, Male(Participants)Population 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/PlaceboTotal
Female38355053176
Male01517
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Population 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/PlaceboTotal
Hispanic or Latino88232261
Not Hispanic or Latino30283232122
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Population 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/PlaceboTotal
American Indian or Alaska Native1411925
Asian0251118
Black or African American133411
White34263123114
Other215715
Population 1: Baseline ESSDAI Total Score
Population 1: Baseline ESSDAI Total Score(score on scale)Population 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/PlaceboTotal
Mean10.1 ± 4.111.4 ± 4.5——10.7 ± 4.3
Population 2: Baseline ESSPRI Total Score
Population 2: Baseline ESSPRI Total Score(score on a scale)Population 1: Placebo/VIB4920Population 1: VIB4920/PlaceboPopulation 2: Placebo/VIB4920Population 2: VIB4920/PlaceboTotal
Mean——6.8 ± 1.27.1 ± 1.66.9 ± 1.4
08

Study locations

63 sites
  • Research Site
    Fullerton, California 92835, United States
  • Research site
    Upland, California 91786, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Wheaton, Maryland 20902, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Salisbury, North Carolina 28144, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77084, United States
  • Research Site
    Houston, Texas 77089, United States
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1114AAH, Argentina
  • Research Site
    Bordeaux, France
  • Research Site
    Brest, France
  • Research Site
    Grenoble, France
  • Research Site
    Paris Cedex 13, France
  • Research Site
    Paris, France
  • Research Site
    Strasbourg, France
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Secunderabad, Andhra Pradesh 5000003, India
  • Research Site
    Ahmedabad, Gujarat 380015, India
  • Research Site
    Bangalore, Karnataka 560010, India
  • Research Site
    Pune, Maharshtra 411001, India
  • Research Site
    Pune, Maharshtra 411013, India
  • Research Site
    Bhubaneswar, Odisha 751005, India
  • Research Site
    Chennai, Tamil Nadu 600004, India
  • Research Site
    Milano, Lambardia 20122, Italy
  • Research Site
    Rome, Lazio 00161, Italy
  • Research Site
    Brescia, Province Of Brescia 25123, Italy
  • Research Site
    Perugia, Umbria 06129, Italy
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    Suwon si, Gyeonggi 16499, Korea, Republic of
  • Research Site
    Incheon, Republic Of Korea 21565, Korea, Republic of
  • Research Site
    Incheon, Republic Of Korea 22332, Korea, Republic of
  • Research Site
    Seoul, Republic Of Korea 06591, Korea, Republic of
  • Research Site
    Saltillo, Coahuila 25000, Mexico
  • Research Site
    Guadalajara, Jalisco 44650, Mexico
  • Research Site
    Guadalajara, Jalisco 44690, Mexico
  • Research Site
    Ciudad de mexico, 06700, Mexico
  • Research Site
    Lima, San Martin De Porres 31, Peru
  • Research Site
    Lima, 1, Peru
  • Research Site
    Lima, 33, Peru
  • Research Site
    Elbląg, Elblag 82-300, Poland
  • Research Site
    Krakow, 30-363, Poland
  • Research Site
    Lublin, 20-412, Poland
  • Research Site
    Poznan, 60-693, Poland
  • Research Site
    Siedlce, 08-110, Poland
  • Research Site
    Szczecin, 71-252, Poland
  • Research Site
    Warszawa, 02-637, Poland
  • Research Site
    Warszawa, 02-691, Poland
  • Research Site
    Wrocław, 02-637, Poland
  • Research Site
    Kaohsiung, 81362, Taiwan
  • Research Site
    Taichung City, 40705, Taiwan
  • Research Site
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • Research Site
    Truro, TR13LJ, United Kingdom
09

References and documents

Publications

  • St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W, Pham TH, Sikora K, Rees WA, Alevizos I. CD40 ligand antagonist dazodalibep in Sjogren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024 Jun;30(6):1583-1592. doi: 10.1038/s41591-024-03009-3. Epub 2024 Jun 5. PubMed 38839899 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Sep 2022, 32 months.

Results were first posted in Apr 2025, 2 years 7 months after primary completion. A results delay was requested in May 2023.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2019
First posted
Oct 16, 2019
StartActual
Dec 9, 2019
Primary completionActual
Sep 1, 2022
CompletionActual
Mar 10, 2023
Results delay requested
May 25, 2023
Results first posted
Apr 30, 2025
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04129164
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Dec 9, 2019
Primary completion
Sep 1, 2022
Completion
Mar 10, 2023
Results posted
Apr 30, 2025
Last update
Apr 30, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazodalibep

Start the discussion